PK UNDER-STUDIED DRUGS IN PREGNANCY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Medication use is very common during pregnancy. Untreated or inadequately treated chronic illness during pregnancy is associated with significant morbidity and mortality for both the mother and her fetus. On average, women take 3 medications during pregnancy, not counting prenatal vitamins. Very little is known about the pharmacokinetics of medications during pregnancy. The little information that we do have suggests that the physiologic changes that occur during pregnancy (increased renal filtration, increased activity of CYP3A, CYP2D6 and CYP2C9 and decreased activity of CYP1A2) significantly alter the way the body handles drugs during pregnancy and therefore changes the needed dosages of medications during pregnancy. In most cases, obstetricians base the dosage of medications during pregnancy on how the drugs are handled in non-pregnant individuals with the added influence of their clinical experience. The purpose of this pilot observational study is to evaluate the pharmacokinetics of medications that pregnant women are already receiving for therapeutic reasons during pregnancy and compare that to postpartum.